Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • ASCO Journal Club • Cancer Prevention • Cancer Predisposition
For which non-BRCA pathogenic germline variants, if any, might you consider recommending chemoprevention with SERM/AI?
In a scenario where patient's other clinical/familial risk does not sufficiently qualify them?
See JCO OGR 8/2021 by @Mark E. Robson discussing management of non-BRCA PVs, and companion study (Kraft et al, 8/2021) evaluating the role of further characterization of polygenic risk score.
Answer from: Medical Oncologist at Academic Institution
The breast cancer prevention trials enrolled women with a risk of developing breast cancer equivalent to a 60-year old woman with no other risk factors. That is not a HIGH risk. Chemoprevention has been dramatically underused in both the truly high risk (if pathogenic mutation carriers) as well as t...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Breast cancers associated with CHEK2 and ATM pathogenic variants are usually ER-positive and thus chemoprevention may be particularly valuable. However, a woman does not need a pathogenic variant for consideration of chemoprevention. Multiple risk models including BCRAT, IBIS, and Can...
Comments
Medical Oncologist at Alvin & Lois Lapidus Cancer Institute Northwest Hospital
When counseling a BRCA1 and BRCA2 patient who is n...
When counseling a BRCA1 and BRCA2 patient who is n...
Answer from: Medical Oncologist at Academic Institution
Breast cancer is a heterogeneous disease, which may be stratified by tumor hormone receptor status. More recent genetic studies have examined germline pathogenic variants with respect to risk of estrogen receptor (ER)-positive or ER-negative breast cancers. For example, PALB2 is associated with incr...
Comments
Medical Oncologist at Southwest Medcl Consult SC
Specific details provided by Dr. @Katherine D. Cre...
Specific details provided by Dr. @Katherine D. Cre...